内容摘要：While coconut aminos are a little bit higher in naturally-occuring sugar (from the coconut sap) than soy sauce, they also contain less than one-third the amount of sodium.

While coconut aminos are a little bit higher in naturally-occuring sugar (from the coconut sap) than soy sauce, they also contain less than one-third the amount of sodium.

is struggling with simple tasks, according to two people familiar with it.The tool — which is still in beta testing — is buggy, doesn’t yet connect to the FDA’s internal systems and has issues when it comes to uploading documents or allowing users to submit questions, the people say. It’s also not currently connected to the internet and can’t access new content, such as recently published studies or anything behind a paywall.

, dubbed internally CDRH-GPT, is intended to help staffers at the agency’s Center for Devices and Radiological Health, a division responsible for ensuring the safety of devices implanted in the body as well as essential tools like X-rays and CT scanners.The division was among those affected by theWhile many of the device reviewers were spared, the agency eliminated much of the backend support that enables them to issue approval decisions on time.

The work of reviewers includes sifting through large amounts of data from animal studies and clinical trials. Depending on the applicant, it can take months or even over a year — which an AI tool could feasibly help shorten.Experts, however, are concerned that the FDA’s push toward AI could outpace what the technology is actually ready for.

Since taking over the agency on April 1, Commissioner Dr. Marty Makary has pushed to integrate artificial intelligence across the FDA’s divisions. How this move into AI could affect the safety and effectiveness of drugs or medical devices hasn’t been determined.

for the AI rollout. On Monday, he said the agency was ahead of schedule.Six days later, Zembruski-Ruple went to Sloan Kettering’s urgent care department to treat sores in her mouth and swelling around her eyes. The hospital diagnosed oral yeast infection and sent her home, her sister and partner said. Two days later, they said, she returned in agony — with severe diarrhea and vomiting — and was admitted. “Enzyme deficiency,” Zembruski-Ruple texted a friend.

The 65-year-old, a patient advocate who had worked for the National Multiple Sclerosis Society and other groups, would never go home.Covered in bruises and unable to swallow or talk, she eventually entered hospice care and

from the very drug that was supposed to extend her life, said her longtime partner, Richard Khavkine. Zembruski-Ruple was deficient in the enzyme that metabolizes capecitabine, the chemotherapy drug she took, said Khavkine and Susan Zembruski, one of her sisters. Zembruski-Ruple was amongor its cousin, the IV drug fluorouracil known as 5-FU.